Viking Therapeutics is trading 10.18% down at $37.41 after announcing on September 23, 2026, separate proposed offerings: $200 million in common stock and $200 million in convertible senior notes due 2032. - The financing raised dilution concerns after a 35.67% gain on September 22. - Proceeds are intended to support VK2735, VK3019, research, working capital and general corporate purposes. - Biotechnology gained 2.61% pre-market; broader equity weakness may add pressure. The offerings remain subject to market conditions and are unpriced.